First National Bank of Omaha Buys Shares of 60,469 Zoetis Inc. $ZTS

First National Bank of Omaha bought a new position in shares of Zoetis Inc. (NYSE:ZTS) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 60,469 shares of the company’s stock, valued at approximately $8,848,000.

Several other large investors have also modified their holdings of the business. Vanguard Group Inc. raised its holdings in Zoetis by 1.0% in the third quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock valued at $6,190,326,000 after acquiring an additional 419,777 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Zoetis by 0.9% in the 2nd quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock valued at $1,721,356,000 after purchasing an additional 95,294 shares in the last quarter. Norges Bank purchased a new stake in shares of Zoetis during the 2nd quarter worth $809,491,000. Brown Advisory Inc. grew its stake in shares of Zoetis by 5.7% during the second quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock worth $726,629,000 after purchasing an additional 250,829 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Zoetis by 113.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after buying an additional 1,995,491 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS opened at $125.45 on Wednesday. The company has a fifty day moving average price of $124.79 and a two-hundred day moving average price of $135.06. The firm has a market capitalization of $52.96 billion, a PE ratio of 20.84, a P/E/G ratio of 2.12 and a beta of 0.96. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.00.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter last year, the business posted $1.40 EPS. The firm’s revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. The ex-dividend date is Monday, April 20th. Zoetis’s payout ratio is currently 35.22%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Piper Sandler reaffirmed a “neutral” rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. UBS Group set a $136.00 price target on Zoetis in a research note on Thursday, January 29th. Barclays assumed coverage on Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price on the stock. Finally, Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, January 28th. Five equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.